| Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons EV Gurevich, JN Joyce Neuropsychopharmacology 20 (1), 60-80, 1999 | 523 | 1999 |
| Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents SM Massa, T Yang, Y Xie, J Shi, M Bilgen, JN Joyce, D Nehama, ... The Journal of clinical investigation 120 (5), 1774-1785, 2010 | 463 | 2010 |
| Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics JN Joyce, A Shane, N Lexow, A Winokur, MF Casanova, JE Kleinman Neuropsychopharmacology 8 (4), 315-336, 1993 | 419 | 1993 |
| Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. AM Murray, HL Ryoo, E Gurevich, JN Joyce Proceedings of the National Academy of Sciences 91 (23), 11271-11275, 1994 | 387 | 1994 |
| Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists SP Presgraves, T Ahmed, S Borwege, JN Joyce Neurotoxicity research 5, 579-598, 2003 | 373 | 2003 |
| PIB is a non-specific imaging marker of amyloid-beta (Aβ) peptide-related cerebral amyloidosis A Lockhart, JR Lamb, T Osredkar, LI Sue, JN Joyce, L Ye, V Libri, ... Brain 130 (10), 2607-2615, 2007 | 369 | 2007 |
| Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia: a postmortem study EV Gurevich, Y Bordelon, RM Shapiro, SE Arnold, RE Gur, JN Joyce Archives of General Psychiatry 54 (3), 225-232, 1997 | 332 | 1997 |
| Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? J Rogers, D Mastroeni, B Leonard, J Joyce, A Grover International review of neurobiology 82, 235-246, 2007 | 315 | 2007 |
| Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs JN Joyce Pharmacology & therapeutics 90 (2-3), 231-259, 2001 | 308 | 2001 |
| Dopamine D3 receptor antagonists as therapeutic agents JN Joyce, MJ Millan Drug discovery today 10 (13), 917-925, 2005 | 298 | 2005 |
| α-Synuclein contributes to GSK-3β-catalyzed Tau phosphorylation in Parkinson’s disease models T Duka, V Duka, JN Joyce, A Sidhu The FASEB Journal 23 (9), 2820, 2009 | 286 | 2009 |
| Effects of estrogen on the basal ganglia C Van Hartesveldt, JN Joyce Neuroscience & Biobehavioral Reviews 10 (1), 1-14, 1986 | 277 | 1986 |
| Alterations in the cortical serotonergic system in schizophrenia: a postmortem study EV Gurevich, JN Joyce Biological psychiatry 42 (7), 529-545, 1997 | 225 | 1997 |
| Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia JN Joyce, N Lexow, E Bird, A Winokur Synapse 2 (5), 546-557, 1988 | 224 | 1988 |
| Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia J Wills, J Jones, T Haggerty, V Duka, JN Joyce, A Sidhu Experimental neurology 225 (1), 210-218, 2010 | 220 | 2010 |
| Ontogeny of dopamine D1 and D2 receptor subtypes in rat basal ganglia: a quantitative autoradiographic study PA Rao, PB Molinoff, JN Joyce Developmental Brain Research 60 (2), 161-177, 1991 | 206 | 1991 |
| Quantitative autoradiography of dopamine D2 sites in rat caudate-putamen: localization to intrinsic neurons and not to neocortical afferents JN Joyce, JF Marshall Neuroscience 20 (3), 773-795, 1987 | 186 | 1987 |
| Serotonergic involvement in haloperidol-induced catalepsy. BS Neal-Beliveau, JN Joyce, I Lucki Journal of Pharmacology and Experimental Therapeutics 265 (1), 207-217, 1993 | 185 | 1993 |
| Environmental complexity modulates growth of granule cell dendrites in developing but not adult hippocampus of rats BA Fiala, JN Joyce, WT Greenough Experimental Neurology 59 (3), 372-383, 1978 | 165 | 1978 |
| Dopamine transporter‐immunoreactive neurons decrease with age in the human substantia nigra SY Ma, BJ Ciliax, G Stebbins, S Jaffar, JN Joyce, EJ Cochran, ... Journal of comparative Neurology 409 (1), 25-37, 1999 | 163 | 1999 |
Manuel CasanovaProfessor of Biomedical Sciences, University of South CarolinaVerified email at louisville.edu
